200 related articles for article (PubMed ID: 12901340)
21. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
Valcárcel D; Martino R
Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
[TBL] [Abstract][Full Text] [Related]
22. [Treatment outcome of myelodysplastic syndrome patients younger than 60 years old].
Matsushima T; Handa H; Yokohama A; Sakura T; Okamoto K; Kawamura T; Tsumita Y; Murayama K; Isoda A; Jinbo T; Hirabyashi H; Sawamura M; Karasawa M; Shimano S; Tsukamoto N; Miyawaki S; Nojima Y; Murakami H
Rinsho Ketsueki; 2003 Oct; 44(10):1004-9. PubMed ID: 14639946
[TBL] [Abstract][Full Text] [Related]
23. Transplant strategies for myelodysplastic syndrome.
McCarty J
Best Pract Res Clin Haematol; 2004 Dec; 17(4):559-72. PubMed ID: 15494294
[TBL] [Abstract][Full Text] [Related]
24. Treatment of pediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia: the Brazilian experience in the past decade.
Valera ET; Latorre Mdo R; Mendes WL; Seber A; Lee ML; de Paula MJ; Loggetto SR; Velloso E; Niero-Melo L; Lopes LF;
Leuk Res; 2004 Sep; 28(9):933-9. PubMed ID: 15234570
[TBL] [Abstract][Full Text] [Related]
25. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
26. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
[TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic syndromes in older adults.
Lindsey M; Beavers J
Clin J Oncol Nurs; 2010 Oct; 14(5):545-7. PubMed ID: 20880813
[TBL] [Abstract][Full Text] [Related]
28. Transplant strategies for patients with myelodysplastic syndromes.
Deeg HJ
Curr Opin Hematol; 2006 Mar; 13(2):61-6. PubMed ID: 16456370
[TBL] [Abstract][Full Text] [Related]
29. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
30. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.
de Witte T; Brand R; van Biezen A; Delforge M; Biersack H; Or R; Meloni G; Bandini B; Sierra J; Kroger N; Gratwohl A; Niederwieser D;
Haematologica; 2006 Jun; 91(6):750-6. PubMed ID: 16769576
[TBL] [Abstract][Full Text] [Related]
31. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes.
American Society for Blood and Marrow Transplantation
Biol Blood Marrow Transplant; 2009 Feb; 15(2):135-6. PubMed ID: 19167675
[No Abstract] [Full Text] [Related]
32. Novel agents for the management of myelodysplastic syndromes.
Meletis J; Viniou N; Terpos E
Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944
[TBL] [Abstract][Full Text] [Related]
33. Update on the therapy for myelodysplastic syndrome.
Kasner MT; Luger SM
Am J Hematol; 2009 Mar; 84(3):177-86. PubMed ID: 19195035
[TBL] [Abstract][Full Text] [Related]
34. Advances in MDS.
Schiffer CA
Clin Adv Hematol Oncol; 2007 Jun; 5(6):450-2. PubMed ID: 17679919
[No Abstract] [Full Text] [Related]
35. The myelodysplastic syndromes and myeloproliferative disorders.
Williams JL
Clin Lab Sci; 2004; 17(4):223-34. PubMed ID: 15559729
[TBL] [Abstract][Full Text] [Related]
36. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
37. Role of chromosome 1 pericentric heterochromatin (1q) in pathogenesis of myelodysplastic syndromes: report of 2 new cases.
Millington K; Hudnall SD; Northup J; Panova N; Velagaleti G
Exp Mol Pathol; 2008 Apr; 84(2):189-93. PubMed ID: 18339374
[TBL] [Abstract][Full Text] [Related]
38. Autologous stem cell transplantation in myelodysplastic syndromes.
de Witte T; Suciu S; Brand R; Muus P; Kröger N
Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
[TBL] [Abstract][Full Text] [Related]
39. Myelodysplastic syndromes clinical practice guidelines in oncology.
Greenberg PL; Baer MR; Bennett JM; Bloomfield CD; De Castro CM; Deeg HJ; Devetten MP; Emanuel PD; Erba HP; Estey E; Foran J; Gore SD; Millenson M; Navarro WH; Nimer SD; O'Donnell MR; Saba HI; Spiers K; Stone RM; Tallman MS
J Natl Compr Canc Netw; 2006 Jan; 4(1):58-77. PubMed ID: 16403405
[No Abstract] [Full Text] [Related]
40. Management of patients with higher risk myelodysplastic syndromes.
Fukumoto JS; Greenberg PL
Crit Rev Oncol Hematol; 2005 Nov; 56(2):179-92. PubMed ID: 15979321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]